Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

P70 S6 kinase inhibitor and MTOR inhibitor combination therapy

A technology of inhibitors and compounds, applied in drug combinations, medical preparations containing active ingredients, muscular system diseases, etc., can solve problems such as growth arrest

Inactive Publication Date: 2013-06-12
ELI LILLY & CO
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Inhibition of mTOR activity in tumor cells has been shown to lead to G1 growth arrest due to translational disruption of regulated cyclins

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • P70 S6 kinase inhibitor and MTOR inhibitor combination therapy
  • P70 S6 kinase inhibitor and MTOR inhibitor combination therapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0008] Compound 4-[4-[4-(4-fluoro-3-trifluoromethyl-phenyl)-1-methyl-1H-imidazol-2-yl]-piperidin-1-yl]-1H-pyridine Azolo[3,4-d]pyrimidine

[0009]

[0010] is a p70 S6 kinase inhibitor.

[0011] Compound 4-[4-[4-(4-fluoro-3-trifluoromethyl-phenyl)-1-methyl-1H-imidazol-2-yl]-piperidin-1-yl]-1H-pyridine Azolo[3,4-d]pyrimidine is a base and as such will react with any of a number of organic and inorganic acids to form pharmaceutically acceptable salts. The term "pharmaceutically acceptable salt" as used herein refers to the compound 4-[4-[4-(4-fluoro-3-trifluoromethyl-phenyl)-1-methyl- Salts of 1H-imidazol-2-yl]-piperidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine. Such salts include the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science, 66, 2-19 (1977), which are known to those skilled in the art. Tosylate (also known as p-toluenesulfonate) and hydrochloride are preferred. Tosylate salts are particularly preferred.

[0012] "mTOR inhibitor" refers to...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a compound 4-[4-[4-(4-fluoro-3-trifluoromethyl-phenyl)-1-methyl-1H-imidazol-2-yl]-piperidine-1- combination therapy of ]-1H-pyrazolo[3,4-d]pyrimidine or a pharmaceutically acceptable salt thereof and an mTOR inhibitor for the treatment of glioblastoma multiforme, colon adenocarcinoma, non-small cell lung cancer , small cell lung cancer, cisplatin-resistant small cell lung cancer, ovarian cancer, leukemia, pancreatic cancer, prostate cancer, breast cancer, renal cell carcinoma, multiple myeloma, Kaposi's sarcoma, Hodgkin's lymphoma, Lymphangioleiomyoma, non-Hodgkin lymphoma, or sarcoma.

Description

Background of the invention [0001] The phosphatidylinositol-3-kinase (PI3K) / AKT / mammalian target of rapamycin (mTOR) pathway encompasses a large number of signaling points critical in the control of cell growth and survival. mTOR is a serine-threonine protein kinase involved in the control of many cellular functions such as cell proliferation, cell survival, protein synthesis and transcription. Inhibition of mTOR activity in tumor cells has been shown to result in arrest of G1 growth due to disruption of translation of regulated cyclins. P70 S6 kinase is a serine-threonine protein kinase that is a downstream effector of the PI3K / AKT / mTOR signaling pathway. P70 S6 kinase phosphorylates the intracellular ribosomal protein S6 and regulates ribosome biogenesis, cell growth and cell cycle progression in response to mitogenic stimuli. P70 S6 kinase is normally activated in many solid tumors. Inhibitors of p70 S6 kinase for the treatment of such tumors are disclosed in WO 2006 / 046...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/436A61K31/519A61K45/06A61P35/00
CPCA61K31/436A61K31/519A61K45/06A61P1/04A61P1/18A61P11/00A61P13/08A61P13/12A61P15/00A61P19/00A61P21/00A61P25/00A61P35/00A61P35/02A61P43/00A61K2300/00
Inventor S.吉加纳奇G.P.多诺霍
Owner ELI LILLY & CO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com